Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
On the other hand, if these organisms ultimately were able to survive outside of controlled space, they might have a particular benefit over natural organisms because they would be resistant to predatory living organisms or natural viruses, that could lead to an unmanaged spread of the synthetic organisms.
In June 2010, Mohannad al-Hassani, head of the Syrian Organisation for Human Rights (Swasiya) and winner of the 2010 Martin Ennals Award for Human Rights Defenders, was convicted of "weakening national morale" and "conveying within Syria false news that could debilitate the morale of the nation." He was sentenced to three years in prison. Sednaya Prison alone housed more than 600 political prisoners. The authorities have kept many for years behind bars, often well past their legal sentence. Mass graves across the country were also discovered by forces from the Syrian transitional government after the fall of the Assad regime in December 2024. In a 2006 report, Human Rights Watch reported on the continued detention of "thousands" of political prisoners in Syria, "many of them members of the banned Muslim Brotherhood and the Communist Party." According to the Syrian Human Rights Committee that there were 4,000 political prisoners held in Syrian jails in 2006.
Emu leather has a distinctive patterned surface, due to a raised area around the feather follicles in the skin; the leather is used in such items as wallets, handbags, shoes and clothes, often in combination with other leathers. The feathers and eggs are used in decorative arts and crafts. In particular, emptied emu eggs have been engraved with portraits, similar to cameos, and scenes of Australian native animals. Mounted Emu eggs and emu-egg containers in the form of hundreds of goblets, inkstands and vases were produced in the second half of the nineteenth century, all richly embellished with images of Australian flora, fauna and indigenous people by travelling silversmiths, founders of a 'new Australian grammar of ornament'. They continued longstanding traditions that can be traced back to the European mounted ostrich eggs of the thirteenth century and Christian symbolism and notions of virginity, fertility, faith and strength. For a society of proud settlers who sought to bring culture and civilisation to their new world, the traditional ostrich-egg goblet, freed from its roots in a society dominated by court culture, was creatively made novel in the Australian colonies as forms and functions were invented to make the objects attractive to a new, broader audience.
== Types == While the initial vaccine in the 1940s was based on inactivated virus, subsequent preparations since the 1960s consist of live virus that has been weakened. It is on the World Health Organization's List of Essential Medicines. There are a number of different types in use as of 2007. Mumpsvax is Merck's brand of Jeryl Lynn strain vaccines. It is a component of Merck's three-virus MMR vaccine, and is the mumps vaccine standard in the United States. Mumpsvax is given by a subcutaneous injection of live virus reconstituted from freeze-dried (lyophilized) vaccine. Production of Mumpsvax as a stand-alone product ceased in 2009. The cells used in culture, virus stocks used, and animal fluids are all screened for extraneous material as part of the vaccine production. They are grown in Medium 199 (a solution containing buffered salt, vitamins, amino acids, fetal bovine serum) with SPGA (sucrose, phosphate, glutamate, human serum albumin) and neomycin. The human albumin processing uses the Cohn cold ethanol fractionation method.
Sources: en.wikipedia.org
== Function == Dermcidin is a secreted protein that is subsequently processed into mature peptides of distinct biological activities. The C-terminal peptide is constitutively expressed in sweat and has antibacterial and antifungal activities. The N-terminal peptide, also known as diffusible survival evasion peptide, promotes neural cell survival under conditions of severe oxidative stress. A glycosylated form of the N-terminal peptide may be associated with cachexia (muscle wasting) in cancer patients.
== Notable alumni == Tassaduq Hussain Jillani, 21st Chief Justice of Pakistan Samar Mubarakmand, nuclear physicist Nawabzada Nasrullah Khan, politician Makhdoom Sajjad Hussain Qureshi, former Governor of Punjab Inzamam-ul-Haq, cricketer and former captain of the Pakistan national cricket team Syed Jamshed Ali, former judge of the Supreme Court of Pakistan Faiz Mohammad Khan, medical physicist specialising in radiation oncology Mazhar Kaleem, novelist Tauqeer Nasir, actor and former director-general of the Pakistan National Council of the Arts Muhammad Ali, Lollywood actor Mohsin Naqvi, Urdu poet Irshad Hussain, chemist and nanomaterials scientist Khalid Masood Khan, poet and columnist Ehsan Wyne, lawyer and politician
Bradykinin is rapidly inactivated in the circulating blood, and it disappears completely in a single pass through the pulmonary circulation. Angiotensin I also disappears in the pulmonary circulation because of its conversion to angiotensin II. Furthermore, angiotensin II passes through the lungs without any loss. The inactivation of bradykinin and the conversion of angiotensin I to angiotensin II in the lungs was thought to be caused by the same enzyme. In 1970, Ng and Vane, using BPF provided by Ferreira, showed the conversion is inhibited during its passage through the pulmonary circulation. BPFs are members of a family of peptides whose potentiating action is linked to inhibition of bradykinin by ACE. Molecular analysis of BPF yielded a nonapeptide BPF teprotide (SQ 20,881), which showed the greatest ACE inhibition potency and hypotensive effect in vivo. Teprotide had limited clinical value as a result of its peptide nature and lack of activity when given orally. In the early 1970s, knowledge of the structure-activity relationship required for inhibition of ACE was growing. David Cushman, Miguel Ondetti and colleagues used peptide analogs to study the structure of ACE, using carboxypeptidase A as a model. Their discoveries led to the development of captopril, the first orally-active ACE inhibitor, in 1975. Captopril was approved by the United States Food and Drug Administration in 1981. The first nonsulfhydryl-containing ACE inhibitor, enalapril, was approved four years later. At least 8 other ACE inhibitors have since been marketed.
Manufactured cigarettes represent the most prevalent form of tobacco consumption globally, accounting for approximately 70% to 80% of all tobacco use. In addition to the inherent risks of tobacco use, manufactured cigarettes have specific engineering and chemical modifications that introduce secondary harms. Modern commercial cigarettes utilize filter ventilation (small perforations in the filter), which were historically marketed to reduce tar but actually encourage "compensatory smoking", where users inhale more deeply to maintain nicotine levels. The manufacturing process also incorporates approximately 600 additives, such as ammonia, which is used to "freebase" nicotine for faster absorption into the brain, and sugars that, when burned, produce the carcinogen acetaldehyde. Nearly all manufactured cigarettes in the U.S. and EU are classified as fire-safe cigarettes, which requires manufacturers to add chemicals to the paper to extinguish the cigarette if left unattended. Some studies and consumer reports have linked these treated papers to increased levels of carbon monoxide and naphthalene in the smoke, as well as unique side effects like increased respiratory irritation and headaches compared to other tobacco products.
2 SO2 + O2 ⇌ 2 SO3 The sulfur trioxide is absorbed into 97–98% H2SO4 to form oleum (H2S2O7), also known as fuming sulfuric acid or pyrosulfuric acid. The oleum is then diluted with water to form concentrated sulfuric acid.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.